glp-1 nejm In the ATTAIN-1 phase 3, randomized trial, the use of orforglipron, an oral glucagon-like peptide-1 receptor agonist, led to significant mean body-weight reductions in patients with obesity, as compared with placebo. Full 𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿

This article explores current clinical evidence, provider decision-making frameworks, and how genetic insights may inform a personalized conversation with your healthcare

METABOLISM SUPPORT: Powered by GreenSelect Phytosome, Clinical research shows this unique green tea extract, when combined with a reduced-calorie diet, can support healthy weight management and a reduced waist size

In addition to lifting dead cells, this formulation tones skin, refines pores, and soothes irritation

GLP-1 receptor agonists were designed for weight management and diabetes, but emerging evidence suggests potential intersections with chronic pain pathways